Planned Solutions Inc. Invests $236,000 in Pfizer Inc. (NYSE:PFE)

Planned Solutions Inc. purchased a new position in shares of Pfizer Inc. (NYSE:PFE) during the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 8,208 shares of the biopharmaceutical company’s stock, valued at approximately $236,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Moneta Group Investment Advisors LLC increased its position in Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after purchasing an additional 160,963,976 shares during the period. Norges Bank bought a new stake in shares of Pfizer in the 4th quarter valued at about $3,150,472,000. Charles Schwab Investment Management Inc. boosted its stake in Pfizer by 10.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after acquiring an additional 9,393,992 shares during the last quarter. Morgan Stanley increased its stake in Pfizer by 10.3% in the fourth quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock valued at $4,073,547,000 after purchasing an additional 7,419,929 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Pfizer during the first quarter worth $311,238,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently weighed in on PFE shares. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. UBS Group reduced their price target on Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a report on Thursday, December 14th. Barclays reduced their price objective on Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a report on Thursday, December 14th. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research note on Thursday, January 4th. Finally, Guggenheim initiated coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $36.88.

Pfizer Price Performance

Shares of NYSE:PFE opened at $27.77 on Thursday. The business has a fifty day moving average price of $27.47 and a 200-day moving average price of $29.47. Pfizer Inc. has a 1-year low of $25.61 and a 1-year high of $42.22. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The company has a market capitalization of $157.25 billion, a PE ratio of 77.14, a PEG ratio of 1.24 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm’s revenue was down 41.3% on a year-over-year basis. During the same quarter last year, the business posted $1.14 earnings per share. As a group, equities analysts expect that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.